Algernon Pharmaceuticals is a Canadian clinical stage drug development and repurposing company investigating multiple drugs for unmet global medical needs. Algernon Pharmaceuticals has active research programs for IPF with chronic cough, and chronic kidney disease, and is the parent company of a newly created private equity subsidiary called Algernon NeuroScience, that is advancing a psychedelic program investigating a proprietary form of psychedelic DMT for stroke and traumatic brain injury (TBI).
Company Profile
Latest Presentation
Corporate Fact Sheet
View Corporate Fact SheetIndustry Classifications
Sector:
Biotechnology
Industry:
Drug Development
NAICS:
Research and Development in the Physical, Engineering, and Life Sciences (541710)
SIC:
Commercial Physical and Biological Research (8731)
Contact Information
Investor Relations
Christopher J. Moreau
Chief Executive Officer
T: 604-398-4175
chris@algernonpharmaceuticals.com
Company Contact
Algernon Pharmaceuticals Inc.
601 West Broadway
Suite 400
Vancouver, BC V5Z 4C2
Canada
T: 604-398-4175
info@algernonpharmaceuticals.com
